Literature DB >> 19836455

Current challenges in chronic graft-versus-host disease.

Gerard Socie1, Jerome Ritz, Paul J Martin.   

Abstract

Chronic graft-versus-host disease (cGVHD), a multiorgan disorder, is the leading cause of late nonrelapse mortality (NRM) after hematopoietic stem cell transplantation (HSCT). Despite many years of experience with this disease we are still faced with numerous challenges including (among others); lack of reliable preclinical models, poor knowledge of human pathophysiology, validated diagnostic and severity criteria, and unpredictable clinical response to first line treatment. We will review recent advances on the 3 last mentioned unresolved areas. Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2009        PMID： 19836455     DOI： 10.1016/j.bbmt.2009.10.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  16 in total

1.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Authors:  Matthew J Hartwell; Umut Özbek; Ernst Holler; Anne S Renteria; Hannah Major-Monfried; Pavan Reddy; Mina Aziz; William J Hogan; Francis Ayuk; Yvonne A Efebera; Elizabeth O Hexner; Udomsak Bunworasate; Muna Qayed; Rainer Ordemann; Matthias Wölfl; Stephan Mielke; Attaphol Pawarode; Yi-Bin Chen; Steven Devine; Andrew C Harris; Madan Jagasia; Carrie L Kitko; Mark R Litzow; Nicolaus Kröger; Franco Locatelli; George Morales; Ryotaro Nakamura; Ran Reshef; Wolf Rösler; Daniela Weber; Kitsada Wudhikarn; Gregory A Yanik; John E Levine; James Lm Ferrara
Journal:  JCI Insight       Date:  2017-02-09

3.  A Canine Model of Chronic Graft-versus-Host Disease.

Authors:  Scott S Graves; Andrew Rezvani; George Sale; Diane Stone; Maura Parker; Steven Rosinski; Michele Spector; Bruce Swearingen; Leslie Kean; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

4.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

Authors:  John E Levine; Thomas M Braun; Andrew C Harris; Ernst Holler; Austin Taylor; Holly Miller; John Magenau; Daniel J Weisdorf; Vincent T Ho; Javier Bolaños-Meade; Amin M Alousi; James L M Ferrara
Journal:  Lancet Haematol       Date:  2014-12-23       Impact factor: 18.959

5.  A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.

Authors:  Sandra A Mitchell; David Jacobsohn; Kimberly E Thormann Powers; Paul A Carpenter; Mary E D Flowers; Edward W Cowen; Mark Schubert; Maria L Turner; Stephanie J Lee; Paul Martin; Michael R Bishop; Kristin Baird; Javier Bolaños-Meade; Kevin Boyd; Jane M Fall-Dickson; Lynn H Gerber; Jean-Pierre Guadagnini; Matin Imanguli; Michael C Krumlauf; Leslie Lawley; Li Li; Bryce B Reeve; Janine Austin Clayton; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

6.  Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Xiaoyu Chai; Paul J Martin; Daniel Weisdorf; Yoshihiro Inamoto; Joseph Pidala; Madan Jagasia; Steven Pavletic; Corey Cutler; Georgia Vogelsang; Sally Arai; Mary E D Flowers; Stephanie J Lee
Journal:  Haematologica       Date:  2015-02-24       Impact factor: 9.941

7.  Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells.

Authors:  Yanwen Peng; Xiaoyong Chen; Qifa Liu; Dijing Xu; Haiqing Zheng; Longshan Liu; Qiuli Liu; Muyun Liu; Zhiping Fan; Jing Sun; Xiaobo Li; Ruifeng Zou; Andy Peng Xiang
Journal:  Stem Cells Transl Med       Date:  2014-07-10       Impact factor: 6.940

8.  Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease.

Authors:  David A Knorr; Hongbo Wang; Mukta Aurora; Margaret L MacMillan; Shernan G Holtan; Rachel Bergerson; Qing Cao; Daniel J Weisdorf; Sarah Cooley; Claudio Brunstein; Jeffery S Miller; John E Wagner; Bruce R Blazar; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-13       Impact factor: 5.742

9.  Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Xiaoyu Chai; Joseph Pidala; Yoshihiro Inamoto; Paul J Martin; Barry Storer; Iskra Pusic; Mary E D Flowers; Mukta Arora; Steven Z Pavletic; Stephanie J Lee
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

10.  Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study.

Authors:  Acf Motta; Q Zhan; A Larson; M Lerman; S-B Woo; R J Soiffer; G F Murphy; N S Treister
Journal:  Oral Dis       Date:  2018-03-13       Impact factor: 3.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.